News from the American Heart Association 2024 Scientific Sessions took seven of the 10 top slots this month.

Pathways to new treatments for heart failure take time—as long as four decades for two now accepted therapies. So, new ...

With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

International heart experts believe the weight-loss drug Ozempic could be given to millions of healthy adults, amid mounting ...

Obesity is a chronic, progressive disease that can lead to serious health complications, reduced quality of life, and ...

In this phase 3 trial, tirzepatide reduced heart failure symptoms and physical limitations while lowering the risk of ...

One of these is reducing the risk of worsening heart failure in adults who have heart failure with preserved ejection ...

Eli Lilly dropped game-changing news on Nov. 16, revealing tirzepatide’s breakthrough results in the SUMMIT Phase 3 trial. Not only did it cut heart failure risks by 38%, but it also delivered ...

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart ...